Moderate to Severe Chronic Plaque-Type Psoriasis
Conditions
Keywords
Psoriasis, Plaque, Inflammatory skin disease, Scaly patches, AIN457, Secukinumab, Moderate to Severe Plaque-type Psoriasis
Brief summary
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of secukinumab in both the fixed interval regimen and the retreatment at start of relapse regimen. All subjects who completed the full study treatment period (52 weeks) in the cores studies CAIN457A2304 and CAIN457A2307 were eligible to participate in this extension study. In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab was used.
Interventions
DRUGAIN457 150 mg
(1 injection per dose) and placebo to Secukinumab 150 mg
DRUGAIN457 300 mg
Secukinumab 150 mg (2 injections per dose)
DRUGPlacebo
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed consent according to local laws and regulations. 2. Subjects who complete Week 52 of study CAIN457A2304 or complete Week 40 of study CAIN457A2307 3. Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator
Exclusion criteria
1. A protocol deviation in the core studies which according to the investigator will prevent the meaningful analysis of the extension study for the individual subject 2. Ongoing use of prohibited psoriasis or non-psoriasis treatments. Time period from last use of prohibited treatments in the core study to first dose of study drug in this extension study. 3. Subjects expected to be exposed to an undue safety risk if participating in the trial 4. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial 5. Plans for administration of live vaccines during the study period 6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>10 mIU/mL).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long-term Safety and Tolerability of Secukinumab | Week 268 | Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52, Week 104, Week 156, Week 208, Week 260 | PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4) |
| Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Baseline, Week 52, Week 104, Week 156, Week 208, Week 260 | PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4) |
| Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52, Week 104, Week 156, Week 208, Week 260 | The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe). The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe. |
| Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Baseline, Week 52, Week 104, Week 156, Week 208, Week 260 | The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions |
| Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52, Week 104, Week 156, Week 208, Week 260 | PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4) |
| EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Baseline, Week 52, Week 104, Week 156 | ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example confined to bed) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state) |
| Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | Week 268 | The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment. |
| Percentage of Patients With Experiencing a Relapse | Week 260 | Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement. |
| Percentage of Patients With Experiencing a Rebound | Up to Week 264 (8 weeks post last dose) | Rebound of disease is defined as a worsening of PASI of \> 125% of the value at baseline (core study), or new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stopping therapy (i.e., if this definition was fulfilled at more than 8 weeks after last study treatment administration, this was defined as rebound like event). PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement. |
| Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52, Week 104, Week 156, Week 208, Week 260 | The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions |
Countries
Austria, Bulgaria, Canada, Czechia, France, Germany, Italy, Japan, Poland, Singapore, Slovakia, Switzerland, United Kingdom, United States, Vietnam
Participant flow
Recruitment details
675 subjects from the core studies (CAIN457A2304 and CAIN457A2307) were enrolled at 112 sites. Subjects enrolled in the secukinumab 300 mg Open-Label (OL) arm came only from the CAIN457A2307 study, as such they were partial responders at Week 12, while all other subjects in the extension were PASI 75 responders at Week 12 in the core study.
Pre-assignment details
At Week 156, subjects who rolled over from the CAIN457A2304 study were unblinded and provided an option to switch to one of the treatment options described below upon investigator judgment; subjects from the CAIN457A2307 study could administer study drug at home every 4 weeks, but were required to come for office visits every 12-16 weeks.
Participants by arm
| Arm | Count |
|---|---|
| AIN150FI AIN457 150 mg - Fixed Interval (FI) | 77 |
| AIN150 FI_AIN300 FI AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW) | 75 |
| AIN300 FI AIN457 300 mg - Fixed Interval (FI) | 168 |
| AIN150 SoR AIN457 150 mg - Start of Relapse (SoR) | 55 |
| AIN150 SOR_AIN300 FI AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW) | 95 |
| AIN300 SoR AIN457 300 mg - Start of Relapse (SoR) | 60 |
| AIN300 SoR _ AIN300 FI AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW) | 112 |
| AIN300 OL AIN457 300 mg Open-label (OL) | 33 |
| Total | 675 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 8 | 3 | 10 | 6 | 1 | 11 | 1 | 3 |
| Overall Study | Death | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Overall Study | Lack of Efficacy | 20 | 1 | 7 | 14 | 0 | 6 | 5 | 6 |
| Overall Study | Lost to Follow-up | 1 | 0 | 6 | 2 | 2 | 3 | 1 | 1 |
| Overall Study | Non-compliance with study treatment | 0 | 0 | 1 | 1 | 1 | 4 | 1 | 0 |
| Overall Study | Physician Decision | 2 | 5 | 2 | 2 | 2 | 3 | 3 | 0 |
| Overall Study | Pregnancy | 3 | 0 | 0 | 4 | 0 | 0 | 2 | 0 |
| Overall Study | Protocol Deviation | 0 | 1 | 2 | 1 | 0 | 1 | 0 | 0 |
| Overall Study | Subject/Guardian decision | 12 | 4 | 13 | 15 | 7 | 19 | 5 | 4 |
Baseline characteristics
| Characteristic | AIN150FI | Total | AIN300 OL | AIN300 SoR _ AIN300 FI | AIN300 SoR | AIN150 SOR_AIN300 FI | AIN150 SoR | AIN300 FI | AIN150 FI_AIN300 FI |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 42.3 Years STANDARD_DEVIATION 13.24 | 45.9 Years STANDARD_DEVIATION 12.74 | 46.5 Years STANDARD_DEVIATION 13.99 | 44.6 Years STANDARD_DEVIATION 13.09 | 45.2 Years STANDARD_DEVIATION 12.08 | 48.0 Years STANDARD_DEVIATION 12.13 | 42.7 Years STANDARD_DEVIATION 12.23 | 48.5 Years STANDARD_DEVIATION 12.54 | 46.0 Years STANDARD_DEVIATION 12.03 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 13 Participants | 123 Participants | 4 Participants | 26 Participants | 9 Participants | 21 Participants | 5 Participants | 31 Participants | 14 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 12 Participants | 0 Participants | 1 Participants | 3 Participants | 3 Participants | 0 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 9 Participants | 0 Participants | 1 Participants | 2 Participants | 3 Participants | 2 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) White | 62 Participants | 528 Participants | 29 Participants | 84 Participants | 45 Participants | 68 Participants | 48 Participants | 132 Participants | 60 Participants |
| Sex: Female, Male Female | 38 Participants | 231 Participants | 12 Participants | 35 Participants | 18 Participants | 28 Participants | 25 Participants | 50 Participants | 25 Participants |
| Sex: Female, Male Male | 39 Participants | 444 Participants | 21 Participants | 77 Participants | 42 Participants | 67 Participants | 30 Participants | 118 Participants | 50 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 132 | 4 / 543 | 4 / 675 |
| other Total, other adverse events | 93 / 132 | 449 / 543 | 542 / 675 |
| serious Total, serious adverse events | 25 / 132 | 119 / 543 | 144 / 675 |
Outcome results
Primary
Long-term Safety and Tolerability of Secukinumab
Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC)
Time frame: Week 268
Population: Safety Set. All subjects who took at least one dose of study treatment during the extension treatment period. A subject with multiple adverse events within a primary system organ class was counted only once in the total row. Deaths up to 28 days after the last dose are included. Only descriptive analysis done.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN150FI | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 88.3 Percentage of participants |
| AIN150FI | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 0.0 Percentage of participants |
| AIN150FI | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 20.8 Percentage of participants |
| AIN150 FI_AIN300 FI | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 1.3 Percentage of participants |
| AIN150 FI_AIN300 FI | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 24.0 Percentage of participants |
| AIN150 FI_AIN300 FI | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 92.0 Percentage of participants |
| AIN300 FI | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 0.6 Percentage of participants |
| AIN300 FI | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 92.9 Percentage of participants |
| AIN300 FI | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 23.8 Percentage of participants |
| AIN150 SoR | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 78.2 Percentage of participants |
| AIN150 SoR | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 16.4 Percentage of participants |
| AIN150 SoR | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 0.0 Percentage of participants |
| AIN150 SOR_AIN300 FI | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 20.0 Percentage of participants |
| AIN150 SOR_AIN300 FI | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 87.4 Percentage of participants |
| AIN150 SOR_AIN300 FI | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 0.0 Percentage of participants |
| AIN300 SoR | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 18.3 Percentage of participants |
| AIN300 SoR | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 80.0 Percentage of participants |
| AIN300 SoR | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 0.0 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 17.0 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 94.6 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 0.0 Percentage of participants |
| AIN300 OL | Long-term Safety and Tolerability of Secukinumab | AEs by Primary System Organ Class (SOC) | 93.9 Percentage of participants |
| AIN300 OL | Long-term Safety and Tolerability of Secukinumab | SAEs by Primary System Organ Class (SOC) | 36.4 Percentage of participants |
| AIN300 OL | Long-term Safety and Tolerability of Secukinumab | Deaths by Primary System Organ Class (SOC) | 6.1 Percentage of participants |
Secondary
EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156
ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example confined to bed) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)
Time frame: Baseline, Week 52, Week 104, Week 156
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| AIN150FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 68.8 Percent change | Standard Deviation 137.47 |
| AIN150FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 61.0 Percent change | Standard Deviation 114.81 |
| AIN150FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 58.6 Percent change | Standard Deviation 122.96 |
| AIN150 FI_AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 52.1 Percent change | Standard Deviation 115.04 |
| AIN150 FI_AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 62.4 Percent change | Standard Deviation 156.21 |
| AIN150 FI_AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 57.0 Percent change | Standard Deviation 137.79 |
| AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 60.6 Percent change | Standard Deviation 140.91 |
| AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 63.0 Percent change | Standard Deviation 137.3 |
| AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 55.2 Percent change | Standard Deviation 114.53 |
| AIN150 SoR | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 125.3 Percent change | Standard Deviation 677.23 |
| AIN150 SoR | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 115.8 Percent change | Standard Deviation 666.41 |
| AIN150 SoR | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 118.5 Percent change | Standard Deviation 689.52 |
| AIN150 SOR_AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 29.5 Percent change | Standard Deviation 70.63 |
| AIN150 SOR_AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 40.2 Percent change | Standard Deviation 94.91 |
| AIN150 SOR_AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 45.1 Percent change | Standard Deviation 102.64 |
| AIN300 SoR | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 152.9 Percent change | Standard Deviation 902.21 |
| AIN300 SoR | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 76.9 Percent change | Standard Deviation 222.97 |
| AIN300 SoR | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 140.3 Percent change | Standard Deviation 778.86 |
| AIN300 SoR _ AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 13.7 Percent change | Standard Deviation 25.16 |
| AIN300 SoR _ AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 41.3 Percent change | Standard Deviation 140.42 |
| AIN300 SoR _ AIN300 FI | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 46.7 Percent change | Standard Deviation 142.85 |
| AIN300 OL | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 77.2 Percent change | Standard Deviation 150.86 |
| AIN300 OL | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 109.5 Percent change | Standard Deviation 373.51 |
| AIN300 OL | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 98.8 Percent change | Standard Deviation 359.93 |
| AIN300 OL | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 104 | 54.3 Percent change | Standard Deviation 84.82 |
| AIN300 OL | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 156 | 68.1 Percent change | Standard Deviation 96.22 |
| AIN300 OL | EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156 | Week 52 | 60.9 Percent change | Standard Deviation 74.18 |
Secondary
Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA)
The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment.
Time frame: Week 268
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only descriptive analysis done.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AIN150FI | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 2 Participants |
| AIN150 FI_AIN300 FI | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 1 Participants |
| AIN300 FI | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 3 Participants |
| AIN150 SoR | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 0 Participants |
| AIN150 SOR_AIN300 FI | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 4 Participants |
| AIN300 SoR | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 0 Participants |
| AIN300 SoR _ AIN300 FI | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 4 Participants |
| AIN300 OL | Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA) | 2 Participants |
Secondary
Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260
The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions
Time frame: Baseline, Week 52, Week 104, Week 156, Week 208, Week 260
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| AIN150FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -90.9 Percent change |
| AIN150FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -70.8 Percent change |
| AIN150FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -89.3 Percent change |
| AIN150FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -77.3 Percent change |
| AIN150FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -87.5 Percent change |
| AIN150 FI_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -85.7 Percent change |
| AIN150 FI_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -84.8 Percent change |
| AIN150 FI_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -73.8 Percent change |
| AIN150 FI_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -81.3 Percent change |
| AIN150 FI_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -67.9 Percent change |
| AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -75.0 Percent change |
| AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -81.8 Percent change |
| AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -73.3 Percent change |
| AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -86.1 Percent change |
| AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -83.3 Percent change |
| AIN150 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -91.7 Percent change |
| AIN150 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -87.5 Percent change |
| AIN150 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -92.1 Percent change |
| AIN150 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -93.3 Percent change |
| AIN150 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -92.3 Percent change |
| AIN150 SOR_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -79.6 Percent change |
| AIN150 SOR_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -65.0 Percent change |
| AIN150 SOR_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -71.9 Percent change |
| AIN150 SOR_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -75.0 Percent change |
| AIN150 SOR_AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -75.0 Percent change |
| AIN300 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -68.2 Percent change |
| AIN300 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -60.6 Percent change |
| AIN300 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -85.7 Percent change |
| AIN300 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -63.6 Percent change |
| AIN300 SoR | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -82.3 Percent change |
| AIN300 SoR _ AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -73.9 Percent change |
| AIN300 SoR _ AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -68.8 Percent change |
| AIN300 SoR _ AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -66.7 Percent change |
| AIN300 SoR _ AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -63.9 Percent change |
| AIN300 SoR _ AIN300 FI | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -74.1 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -66.7 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -74.9 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -83.3 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -84.6 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -72.8 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 260 | -80.0 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 208 | -81.7 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 52 | -79.2 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 104 | -77.2 Percent change |
| AIN300 OL | Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260 | Week 156 | -80.0 Percent change |
Secondary
Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260
The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe). The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe.
Time frame: Week 52, Week 104, Week 156, Week 208, Week 260
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN150FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 62.5 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 59.2 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 55.2 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 51.7 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 57.1 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 47.1 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 48.2 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 30.1 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 21.3 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 50.7 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 39.8 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 55.0 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 50.5 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 35.7 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 50.6 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 56.8 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 69.1 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 65.0 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 66.4 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 62.1 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 37.5 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 20.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 40.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 20.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 41.7 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 14.9 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 63.2 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 20.0 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 16.0 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 58.2 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 30.8 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 28.3 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 17.6 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 25.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 8.3 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 15.3 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 17.3 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 52.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 19.8 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 54.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / IGA 0/1 | 23.8 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / IGA 0/1 | 23.3 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / IGA 0/1 | 37.5 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / IGA 0/1 | 42.4 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / IGA 0/1 | 28.6 Percentage of Participants |
Secondary
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260
PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)
Time frame: Week 52, Week 104, Week 156, Week 208, Week 260
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 89.7 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 63.3 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 80.0 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 85.0 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 69.7 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 78.3 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 71.4 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 49.3 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 54.8 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 65.3 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 58.6 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 61.7 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 77.6 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 67.5 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 78.8 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 87.9 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 88.5 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 78.4 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 80.9 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 88.9 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 40.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 38.2 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 62.5 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 50.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 63.6 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 39.4 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 38.9 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 86.1 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 87.4 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 35.1 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 41.7 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 65.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 55.9 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 51.7 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 53.8 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 44.5 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 39.6 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 41.4 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 79.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 81.6 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 260 | 75.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 104 | 63.3 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 52 | 63.6 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 208 | 61.9 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260 | Week 156 | 57.1 Percentage of Participants |
Secondary
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260
PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)
Time frame: Week 52, Week 104, Week 156, Week 208, Week 260
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 89.5 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 88.3 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 61.8 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 100.0 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 45.0 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 51.4 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 31.6 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 100.0 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 100.0 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 51.7 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 60.0 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 28.6 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 46.7 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 28.3 Percentage of Participants |
| AIN150FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 31.0 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 6.8 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 84.9 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 23.3 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 20.3 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 96.4 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 17.3 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 38.7 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 8.0 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 98.7 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 86.7 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 97.1 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 16.0 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 17.9 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 49.3 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 46.4 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 33.8 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 50.3 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 86.5 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 32.2 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 20.9 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 48.2 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 97.6 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 16.5 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 50.0 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 22.4 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 23.8 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 94.0 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 91.3 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 23.1 Percentage of Participants |
| AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 98.1 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 68.5 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 43.8 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 61.9 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 64.5 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 97.1 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 41.7 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 97.0 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 65.9 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 43.4 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 43.2 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 97.5 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 66.4 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 41.0 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 96.7 Percentage of Participants |
| AIN150 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 98.8 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 10.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 27.3 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 80.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 72.7 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 6.3 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 12.7 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 80.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 30.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 100.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 31.3 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 16.7 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 3.6 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 10.0 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 93.8 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 9.1 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 23.0 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 64.4 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 2.1 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 57.0 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 1.1 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 88.3 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 87.2 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 98.9 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 9.6 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 29.1 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 4.3 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 11.6 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 86.3 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 10.6 Percentage of Participants |
| AIN300 SoR | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 97.5 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 91.4 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 16.7 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 30.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 0.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 100.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 0.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 100.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 7.7 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 7.7 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 19.0 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 8.6 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 88.2 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 14.7 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 5.9 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 85.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 54.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 53.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 18.4 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 95.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 90.1 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 93.1 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 85.5 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 3.6 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 88.3 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 10.8 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 18.2 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 4.5 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 3.6 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 24.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 12.6 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 90 | 23.8 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 100 | 25.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 90 | 43.8 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 90 | 26.7 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 50 | 86.7 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 / PASI 50 | 87.5 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 100 | 23.8 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 50 | 90.5 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 50 | 93.9 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 / PASI 50 | 95.2 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 / PASI 100 | 13.3 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 100 | 19.0 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 / PASI 90 | 28.6 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 90 | 39.4 Percentage of Participants |
| AIN300 OL | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 / PASI 100 | 9.1 Percentage of Participants |
Secondary
Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260
The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions
Time frame: Week 52, Week 104, Week 156, Week 208, Week 260
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN150FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 54.5 Percentage of participants |
| AIN150FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 55.2 Percentage of participants |
| AIN150FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 59.7 Percentage of participants |
| AIN150FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 62.2 Percentage of participants |
| AIN150FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 66.7 Percentage of participants |
| AIN150 FI_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 37.3 Percentage of participants |
| AIN150 FI_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 57.3 Percentage of participants |
| AIN150 FI_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 54.4 Percentage of participants |
| AIN150 FI_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 47.2 Percentage of participants |
| AIN150 FI_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 52.9 Percentage of participants |
| AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 56.1 Percentage of participants |
| AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 47.4 Percentage of participants |
| AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 58.6 Percentage of participants |
| AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 54.7 Percentage of participants |
| AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 50.7 Percentage of participants |
| AIN150 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 65.5 Percentage of participants |
| AIN150 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 64.7 Percentage of participants |
| AIN150 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 70.5 Percentage of participants |
| AIN150 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 72.7 Percentage of participants |
| AIN150 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 67.4 Percentage of participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 43.8 Percentage of participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 32.7 Percentage of participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 41.2 Percentage of participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 30.8 Percentage of participants |
| AIN150 SOR_AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 60.0 Percentage of participants |
| AIN300 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 33.0 Percentage of participants |
| AIN300 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 35.5 Percentage of participants |
| AIN300 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 62.5 Percentage of participants |
| AIN300 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 55.7 Percentage of participants |
| AIN300 SoR | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 34.7 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 38.1 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 32.5 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 28.3 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 42.9 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 15.6 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 38.5 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 41.5 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 56.3 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 59.0 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 41.4 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 260 | 50.0 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 52 | 54.5 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 208 | 52.4 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 104 | 36.7 Percentage of participants |
| AIN300 OL | Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260 | Week 156 | 50.0 Percentage of participants |
Secondary
Percentage of Patients With Experiencing a Rebound
Rebound of disease is defined as a worsening of PASI of \> 125% of the value at baseline (core study), or new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stopping therapy (i.e., if this definition was fulfilled at more than 8 weeks after last study treatment administration, this was defined as rebound like event). PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.
Time frame: Up to Week 264 (8 weeks post last dose)
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AIN150FI | Percentage of Patients With Experiencing a Rebound | 11.5 Percentage of participants |
| AIN150 FI_AIN300 FI | Percentage of Patients With Experiencing a Rebound | 5.8 Percentage of participants |
| AIN300 FI | Percentage of Patients With Experiencing a Rebound | 5.0 Percentage of participants |
| AIN150 SoR | Percentage of Patients With Experiencing a Rebound | 9.4 Percentage of participants |
| AIN150 SOR_AIN300 FI | Percentage of Patients With Experiencing a Rebound | 1.1 Percentage of participants |
| AIN300 SoR | Percentage of Patients With Experiencing a Rebound | 6.9 Percentage of participants |
| AIN300 SoR _ AIN300 FI | Percentage of Patients With Experiencing a Rebound | 10.6 Percentage of participants |
| AIN300 OL | Percentage of Patients With Experiencing a Rebound | 13.0 Percentage of participants |
Secondary
Percentage of Patients With Experiencing a Relapse
Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.
Time frame: Week 260
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AIN150FI | Percentage of Patients With Experiencing a Relapse | 31.2 Percentage of Participants |
| AIN150 FI_AIN300 FI | Percentage of Patients With Experiencing a Relapse | 40.0 Percentage of Participants |
| AIN300 FI | Percentage of Patients With Experiencing a Relapse | 19.6 Percentage of Participants |
| AIN150 SoR | Percentage of Patients With Experiencing a Relapse | 61.8 Percentage of Participants |
| AIN150 SOR_AIN300 FI | Percentage of Patients With Experiencing a Relapse | 52.6 Percentage of Participants |
| AIN300 SoR | Percentage of Patients With Experiencing a Relapse | 43.3 Percentage of Participants |
| AIN300 SoR _ AIN300 FI | Percentage of Patients With Experiencing a Relapse | 56.3 Percentage of Participants |
| AIN300 OL | Percentage of Patients With Experiencing a Relapse | 36.4 Percentage of Participants |
Secondary
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260
PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)
Time frame: Baseline, Week 52, Week 104, Week 156, Week 208, Week 260
Population: The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| AIN150FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -78.13 Percent change | Standard Deviation 26.278 |
| AIN150FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -88.75 Percent change | Standard Deviation 10.928 |
| AIN150FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -83.54 Percent change | Standard Deviation 21.744 |
| AIN150FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -90.27 Percent change | Standard Deviation 11.543 |
| AIN150FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -87.60 Percent change | Standard Deviation 12.296 |
| AIN150 FI_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -81.47 Percent change | Standard Deviation 16.179 |
| AIN150 FI_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -85.06 Percent change | Standard Deviation 14.082 |
| AIN150 FI_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -72.47 Percent change | Standard Deviation 24.099 |
| AIN150 FI_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -84.10 Percent change | Standard Deviation 15.012 |
| AIN150 FI_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -71.48 Percent change | Standard Deviation 19.892 |
| AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -85.68 Percent change | Standard Deviation 13.867 |
| AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -85.91 Percent change | Standard Deviation 13.501 |
| AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -82.51 Percent change | Standard Deviation 19.147 |
| AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -78.02 Percent change | Standard Deviation 19.576 |
| AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -75.02 Percent change | Standard Deviation 25.168 |
| AIN150 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -90.06 Percent change | Standard Deviation 14.639 |
| AIN150 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -88.48 Percent change | Standard Deviation 16.273 |
| AIN150 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -88.34 Percent change | Standard Deviation 15.555 |
| AIN150 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -90.46 Percent change | Standard Deviation 14.116 |
| AIN150 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -91.14 Percent change | Standard Deviation 13.377 |
| AIN150 SOR_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -76.20 Percent change | Standard Deviation 17.418 |
| AIN150 SOR_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -78.97 Percent change | Standard Deviation 16.709 |
| AIN150 SOR_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -63.17 Percent change | Standard Deviation 28.596 |
| AIN150 SOR_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -65.13 Percent change | Standard Deviation 23.452 |
| AIN150 SOR_AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -72.64 Percent change | Standard Deviation 24.394 |
| AIN300 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -89.36 Percent change | Standard Deviation 12.978 |
| AIN300 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -89.40 Percent change | Standard Deviation 12.763 |
| AIN300 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -67.91 Percent change | Standard Deviation 21.521 |
| AIN300 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -68.40 Percent change | Standard Deviation 18.057 |
| AIN300 SoR | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -68.71 Percent change | Standard Deviation 18.094 |
| AIN300 SoR _ AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -74.38 Percent change | Standard Deviation 13.817 |
| AIN300 SoR _ AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -75.63 Percent change | Standard Deviation 16.97 |
| AIN300 SoR _ AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -77.40 Percent change | Standard Deviation 18.714 |
| AIN300 SoR _ AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -67.62 Percent change | Standard Deviation 40.039 |
| AIN300 SoR _ AIN300 FI | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -78.13 Percent change | Standard Deviation 10.197 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -70.98 Percent change | Standard Deviation 19.72 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -85.48 Percent change | Standard Deviation 17.116 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -69.77 Percent change | Standard Deviation 18.586 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -85.25 Percent change | Standard Deviation 17.018 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -69.13 Percent change | Standard Deviation 18.976 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 260 | -81.47 Percent change | Standard Deviation 21.335 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 104 | -76.10 Percent change | Standard Deviation 19.342 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 208 | -79.12 Percent change | Standard Deviation 16.827 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 52 | -79.75 Percent change | Standard Deviation 17.045 |
| AIN300 OL | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260 | Week 156 | -76.12 Percent change | Standard Deviation 20.437 |